Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer

Learn more about:
Related Clinical Trial
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule Optimising Molecular Radionuclide Therapy Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer Function Integrity of Neck Anatomy in Thyroid Surgery An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Evaluation of a New CZT System Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain A Study Into the Effect of Seprafilm in Open Total Thyroidectomy Lenvatinib and Pembrolizumab in DTC Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Influence of Thyroid Hormones on the Woundhealing Process ctDNA in Patients With Thyroid Nodules Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine Trial of LBH589 in Metastatic Thyroid Cancer Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma Thyroid Cancer and Sunitinib Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients Lipid Metabolic Status in Thyroid Carcinoma

Brief Title

Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer

Official Title

Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer.

Brief Summary

      Medullary thyroid carcinoma (MTC) is a rare tumor arising from C cells of the thyroid gland
      and belonging to the endocrine tumors. 18F-DOPA PET, based on tha capacity of endocrine tumor
      cells to take-up, decarboxylate and store amino-acids, such 3-4-dihydroxyphenylalanine(DOPA),
      is used for imaging endocrine tumors. The aim of the study was to evaluate the contribution
      of 18F-DOPA whole-body PET for the detection of recurrences in patients with proven recurrent
      MTC without evidence of recurrence or metastases on several imaging modalities.

Detailed Description

      In patients MTC and persistently elevated calcitonin levels, the challenge is finding the
      site of residual disease. Since the only satisfying treatment is surgery, the early detection
      and precise location is important. Tumor localization techniques usually performed, including
      ultrasonography of the neck and liver, chest and abdomen, bone scintigraphy, isotopic
      scanning and even PET with FDG are poorly sensitive. The use of 18F-DOPA may be more
      sensitive and specific engineering for localization metastatic disease. The study include 100
      patient with persistent MTC demonstrated by elevated tumor markers (calcitonin and CEA) and
      no evidence of recurrence on morphological imaging procedures. 18F-DOPA whole-body PET is
      performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA, the patient fasted for 6
      hours prior the start of the examination.

      All 18F-DOPA PET are evaluated independently by two experienced nuclear medicine physicians
      and any tracer accumulation exceeding the normal uptake tissue is rated as pathologic
      finding. The sensibility and efficiency of 18F-DOPA PET will be analysed and Malignant tissue
      confirmed by histology after surgery or biopsy or by follow-up for one year.

Study Phase

Phase 2

Study Type


Primary Outcome

Any tracer accumulation exceeding the normal uptake tissue searched by two experienced nuclear medicine physicians and compared by malignant tissue confirmed by histology after biopsy, surgery or by follow-up for one year.


Thyroid Neoplasm



Study Arms / Comparison Groups

Description:  18F-L6DOPA PET


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

August 2007

Completion Date

February 2010

Primary Completion Date

August 2009

Eligibility Criteria

        Inclusion criteria:

          -  Patients up to 18 years old with medullary thyroid cancer / carcinoma

          -  Patients with medullary thyroid cancer / carcinoma recurrence, which have a high
             calcitonin level / rate, more than 100pg/ml, associated - or not - to a high CEA
             (Carcinoembryonic Antibodies) level / rate, dated from less than 3 months

          -  Patients with a less than 3 months conventional imaging checkup (cervical
             ultrasonography, cervical-chest-abdomen tomography and / or magnetic resonance
             imaging, abdomen ultrasonography, osseous / bones radionuclide imaging), in which the
             tumor site not certainty located

          -  Informed Consent Form signed and dated by patients

          -  Patients which are "SECURITE SOCIALE" affiliated

        Exclusion criteria:

          -  Pregnant or suckling women

          -  Women able to procreate, without efficient birth control

          -  Patients already included in another Nuclear Medicine or Imaging research protocol
             using ionizing radiations; the efficient dose accumulation will not exceed 20 mSv.




18 Years - N/A

Accepts Healthy Volunteers



Badia-Ourkia HELAL, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Study Sponsor

Assistance Publique - Hôpitaux de Paris

Study Sponsor

Badia-Ourkia HELAL, MD, Principal Investigator, Assistance Publique - Hôpitaux de Paris Hôpital Antoine Béclère

Verification Date

May 2010